Clinical-haematological changes and predictors of severity in acute food protein-induced enterocolitis syndrome reactions at oral food challenge: a multicentre observational study.

Food protein-induced enterocolitis syndrome (FPIES) allergic reaction children diagnosis food allergy oral food challenge paediatrics prognosis severity

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 24 07 2023
revised: 26 04 2024
accepted: 14 05 2024
medline: 26 5 2024
pubmed: 26 5 2024
entrez: 25 5 2024
Statut: aheadofprint

Résumé

Oral food challenge (OFC) is the gold standard for diagnosis of acute Food Protein-Induced Enterocolitis Syndrome (FPIES). No diagnostic/prognostic biomarkers are available, and OFC assessment criteria are not validated. To assess clinical-haematological changes and predictors of severity of FPIES reactions at OFC. Observational multicentre prospective study. Children aged 0-18 years diagnosed with acute FPIES were recruited at follow-up OFC in 12 tertiary centres in Spain and Italy. OFC Outcomes (as positive/negative/inconclusive and mild/moderate/severe) were assessed based on published '2017 FPIES Consensus' criteria. Clinical characteristics were recorded, and full blood count was done at baseline, reaction onset and 4 hours later. Regression analysis was performed to assess predictors of severe reactions at OFC. 81 children had positive OFC (mild in 11% (9/81), moderate in 61% (49/81), severe in 28% (23/81)). Increase in neutrophils and reduction in eosinophils, basophils and lymphocytes was observed (P-value<0.05). OFC was inconclusive in 19 cases despite objective signs or neutrophilia. Regression analysis showed a 2-day OFC protocol where only 25% of an age-appropriate portion is given on day 1 (not gender, age, culprit food, cumulative dose and previous reaction severity) was associated with reduced odds of severe reaction compared to giving multiple doses in a single day. Distinct haematological changes may help support FPIES diagnosis. Current OFC assessment criteria may not capture the broad spectrum of acute FPIES presentations. This 2-day protocol may associate a reduced risk of severe reactions. Future work should aim to develop safer OFC and non-OFC diagnostics for FPIES.

Sections du résumé

BACKGROUND BACKGROUND
Oral food challenge (OFC) is the gold standard for diagnosis of acute Food Protein-Induced Enterocolitis Syndrome (FPIES). No diagnostic/prognostic biomarkers are available, and OFC assessment criteria are not validated.
OBJECTIVE OBJECTIVE
To assess clinical-haematological changes and predictors of severity of FPIES reactions at OFC.
METHODS METHODS
Observational multicentre prospective study. Children aged 0-18 years diagnosed with acute FPIES were recruited at follow-up OFC in 12 tertiary centres in Spain and Italy. OFC Outcomes (as positive/negative/inconclusive and mild/moderate/severe) were assessed based on published '2017 FPIES Consensus' criteria. Clinical characteristics were recorded, and full blood count was done at baseline, reaction onset and 4 hours later. Regression analysis was performed to assess predictors of severe reactions at OFC.
RESULTS RESULTS
81 children had positive OFC (mild in 11% (9/81), moderate in 61% (49/81), severe in 28% (23/81)). Increase in neutrophils and reduction in eosinophils, basophils and lymphocytes was observed (P-value<0.05). OFC was inconclusive in 19 cases despite objective signs or neutrophilia. Regression analysis showed a 2-day OFC protocol where only 25% of an age-appropriate portion is given on day 1 (not gender, age, culprit food, cumulative dose and previous reaction severity) was associated with reduced odds of severe reaction compared to giving multiple doses in a single day.
CONCLUSION CONCLUSIONS
Distinct haematological changes may help support FPIES diagnosis. Current OFC assessment criteria may not capture the broad spectrum of acute FPIES presentations. This 2-day protocol may associate a reduced risk of severe reactions. Future work should aim to develop safer OFC and non-OFC diagnostics for FPIES.

Identifiants

pubmed: 38796100
pii: S2213-2198(24)00538-5
doi: 10.1016/j.jaip.2024.05.024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

L Argiz (L)

Department of Allergy, Clínica Universidad de Navarra, Pamplona, Spain; RICORS Red De Enfermedades Inflamatorias (REI) - RD21/0002/0028, Madrid, Spain. Electronic address: largizalvarez@gmail.com.

M Valsami-Fokianos (M)

Allergy MSc graduate, National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: maria.valsami-fokianos20@imperial.ac.uk.

S Arasi (S)

Allergy Unit, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital (IRCCS, Rome, Italy). Electronic address: stefania.arasi@opbg.net.

S Barni (S)

Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Electronic address: simonabarni@hotmail.com.

S Boscia (S)

Division of Immunology, Meyer Children's Hospital IRCCS, Florence, Italy; Department of Health Sciences, University of Florence, Florence, Italy.

G Bracaglia (G)

Laboratory Medicine, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.

T Bracamonte (T)

Paediatric Allergy Section, Severo Ochoa University Hospital, Madrid, Spain. Electronic address: tbracamonteb@gmail.com.

I Carballeira (I)

Paediatric Allergy Section, Arquitecto Marcide Hospital, Coruña, Spain. Electronic address: iria.carballeira.glez@gmail.com.

G Dinardo (G)

Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.

L Echeverria (L)

Paediatric Allergy Section, Severo Ochoa University Hospital, Madrid, Spain. Electronic address: lecheverria3@gmail.com.

E Garcia (E)

Paediatric Allergy Section, Arquitecto Marcide Hospital, Coruña, Spain. Electronic address: emiliogarcia@mundo-r.com.

C Garcia-Magan (C)

Paediatrics Department. Hospital Clínico Universitario de Santiago de Compostela, Coruña, Spain. Electronic address: cgarciamagan@gmail.com.

J Gomez-Rial (J)

Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: Jose.Gomez.Rial@sergas.es.

P Gonzalez-Delgado (P)

Allergy Department, General University Hospital, Alicante, Spain. Electronic address: purifica60@gmail.com.

A Fiocchi (A)

Allergy Unit, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital (IRCCS, Rome, Italy). Electronic address: alessandro.fiocchi@allegriallergia.net.

T Garriga (T)

Paediatric Allergy Section, Vall D'Hebron University Hospital, Growth and Development Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain. Electronic address: teresa.garriga@vallhebron.cat.

T Ibrahim (T)

Allergy MSc graduate, National Heart and Lung Institute, Imperial College London, London, UK; Allergy and Immunology Division, Hamad Medical Corporation, Doha , Qatar. Electronic address: tibrahim2@hamad.qa.

S Infante (S)

Pediatric Allergy Unit, Hospital General Universitario Gregorio Marañón, Gregorio Marañón Health Research Institute (IiSGM, Madrid, Spain). Electronic address: sonsoles.infante@salud.madrid.org.

A Machinena (A)

Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain. Electronic address: amachinena@sjdhospitalbarcelona.org.

G Mangone (G)

Division of Immunology, Meyer Children's Hospital IRCCS, Florence, Italy. Electronic address: giusi.mangone@tiscali.it.

F Mori (F)

Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Electronic address: f.mori@meyer.it.

J D Moure (JD)

Paediatrics Department. Hospital Clínico Universitario de Santiago de Compostela, Coruña, Spain. Electronic address: Jose.Domingo.Moure.Gonzalez@sergas.es.

V O'Valle (V)

Paediatric Allergy Section, Severo Ochoa University Hospital, Madrid, Spain. Electronic address: virgiovalle@gmail.com.

M Pascal (M)

Immunology Department, CDB, Hospital Clínic de Barcelona, Barcelona, Spain; IDIBAPS, Universitat de Barcelona, Barcelona, Spain. Electronic address: mpascal@clinic.cat.

V Pecora (V)

Allergy Unit, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital (IRCCS, Rome, Italy). Electronic address: stefania.arasi@opbg.net.

A Prieto (A)

Paediatric Allergy Section, General University Hospital, Malaga, Spain. Electronic address: anaanap@hotmail.com.

S Quevedo (S)

Paediatric Allergy Section, Severo Ochoa University Hospital, Madrid, Spain. Electronic address: sergiojosequevedo@yahoo.es.

A Salas-Ellacuriaga (A)

Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain; Unidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Galicia, Spain. Electronic address: antoniosalasellacuriaga@gmail.com.

S Vazquez-Cortes (S)

Allergy Department, Clinico San Carlos Hospital, Madrid, Spain. Electronic address: sonia.vazquez.cortes@gmail.com.

L Vila (L)

Paediatric Allergy Section, Teresa Herrera Hospital, Coruna, Spain. Electronic address: Leticia.Vila.Sexto@sergas.es.

F Martinon-Torres (F)

Paediatrics Department. Hospital Clínico Universitario de Santiago de Compostela, Coruña, Spain; Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: Federico.Martinon.Torres@sergas.es.

A Gomez-Carballa (A)

Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), University of Santiago de Compostela, Santiago de Compostela, Spain; Unidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago de Compostela (SERGAS), Galicia, Spain. Electronic address: Alberto.Gomez.Carballa@sergas.es.

R J Boyle (RJ)

Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: r.boyle@imperial.ac.uk.

M Vazquez-Ortiz (M)

Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: m.vazquez-ortiz@imperial.ac.uk.

Classifications MeSH